Role of the RANK/RANKL pathway in breast cancer

Maturitas

Volumn 86, Issue , 2016, Pages 10-16

  Kiesel, Ludwig ^a   Kohl, Annemarie ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Breast; Cancer; Denosumab; Progesterone; Progestin; RANKL

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROGESTERONE; PROGESTERONE RECEPTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; BONE DENSITY CONSERVATION AGENT;

BONE METASTASIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM CELL; BREAST METASTASIS; CANCER PREVENTION; CANCER THERAPY; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; JAW OSTEONECROSIS; NONHUMAN; OSTEOPOROSIS; REVIEW; BONE NEOPLASMS; BREAST; BREAST TUMOR; CELL TRANSFORMATION; DRUG EFFECTS; FEMALE; METABOLISM; SIGNAL TRANSDUCTION;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DENOSUMAB; FEMALE; HUMANS; OSTEOPOROSIS; PROGESTERONE; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84959422239     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2016.01.001     Document Type: Review

References (110)

1. A.E. Kearns, S. Khosla, and P.J. Kostenuik Receptor activator of nuclear factor B ligand and osteoprotegerin regulation of bone remodeling in health and disease Endocr. Rev. 29 2 2008 155 192
2. W.S. Simonet, D.L. Lacey, C. Dunstan, M. Kelly, M.S. Chang, R. Luthy, H.Q. Nhuyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliot, A. Colombero, H.L. Tan, G. Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw-Gegg, T.M. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Derby, R. Lee, and W.J. Boyle Osteoprotegerin a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
3. T. Akatsu, T. Murakami, K. Ono, M. Nishikawa, E. Tsuda, S.I. Mochizuki, N. Fujise, K. Higashio, K. Motoyoshi, M. Yamamoto, and N. Nagata Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy Bone 23 1998 495 498
4. Y. Hakeda, Y. Kobayashi, K. Yamaguchi, H. Yasuda, E. Tsuda, K. Higashio, T. Miyata, and M. Kumegawa Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts Biochem. Biophys. Res. Commun. 251 1998 796 801
5. T. Burgess, Y.X. Qian, S. Kaufman, B.D. Ring, G. Van, C. Capparelli, M. Kelley, H. Hsu, W.J. Boyle, C.R. Dunstan, S. Hu, and D.L. Lacey The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts J. Cell Biol. 145 1999 527 538
6. H. Yasuda, N. Shima, N. Nakagawa, S.I. Mochizuki, K. Yano, N. Fujise, Y. Sato, T. Kanno, A. Murakami, E. Tsuda, T. Morinaga, and K. Higashio Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 139 1998 1329 1337
7. L.A. Schneeweis, D. Willard, and M.E. Milla Functional dissociation of osteoprotegerin and its interaction with receptor activator of NF-B ligand J. Biol. Chem. 280 2005 41155 41164
8. W.C. Dougall, M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel, T. De Smedt, E. Daro, J. Smith, M.E. Tometsko, C.R. Malisczewski, A. Armstrong, V. Shen, S. Bain, D. Cosman, D. Anderson, P.J. Morrissey, J.J. Peschon, and J. Schuh RANK is essential for osteoclast and lymph node development Genes Dev. 13 1999 2412 2424
9. Y. Kang, P.M. Siegel, W. Shu, M. Drobnjak, S.M. Kakonen, C. Cordon-Cardo, and et al. A multigenic program mediating breast cancer metastasis to bone Cancer Cell 3 2003 537 549
10. W.C. Dougall Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis Clin. Cancer Res. 18 2012 326 335
11. B. Wong, R. Josien, S.Y. Lee, B. Sauter, H.L. Li, R.M. Steinman, and Y. Choi TRANCE (tumor necrosis factor [TNF]-related activationinduced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor J. Exp. Med. 186 1997 2075 2080
12. S. Bord, D.C. Ireland, S.R. Beavan, and J.E. Compston The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts Bone 32 2003 136 141
13. Y. Nakamichi, N. Udagawa, H. Yasuda, M. Nakamura, Y. Kobayashi, and N. Takahashi M-CSF independent mechanisms for osteoclastogenesis J. Bone Min. Res. 22 2007 S380
14. N. Giuliani, S. Colla, R. Sala, M. Moroni, M. Lazzaretti, S. La Monica, S. Bonomini, M. Hojden, G. Sammarelli, S. Barille, R. Bataille, and V. Rizzoli Human myeloma cells stimulate the receptor activator of nuclear factor-B ligand (RANKL) in T lymphocytes: A potential role in multiple myeloma bone disease Blood 100 2002 4615 4621
15. Y.Y. Kong, U. Feige, I. Sarosi, B. Bolon, A. Tafuri, S. Morony, C. Capparelli, J. Li, R. Elliot, S. McCabe, T. Wong, G. Campagnuolo, E. Moran, E.R. Bogoch, G. Van, L.T. Nguyen, P.S. Ohashi, D.L. Lacey, E. Fish, W.J. Boyle, and J.M. Penninger Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 402 1999 304 309
16. Y. Nakamichi, N. Udagawa, Y. Kobayashi, M. Nakamura, Y. Yamamoto, T. Tamashita, T. Mizoguchi, M. Sato, M. Mogi, J.M. Penninger, and N. Takahashi Osteoprotegerin reduces the serum level of receptor activator of NF-B ligand derived from osteoblasts J. Immunol. 178 2007 192 200
17. T. Ikeda, M. Kasai, M. Utsuyama, and K. Hirokawa Determination of three isoforms of the receptor activator of nuclear factor-B ligand and their differential expression in bone and thymus Endocrinology 142 2001 1419 1426
18. A. Hikita, I. Yana, H. Wakeyama, M. Nakamura, Y. Kadono, Y. Oshima, K. Nakamura, M. Seiki, and S. Tanaka Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-B ligand J. Biol. Chem. 281 2006 36846 36855
19. J. Li, I. Sarosi, X.Q. Yan, S. Morony, C. Capparelli, H.L. Tan, S. McCabe, R. Elliot, S. Scully, G. Van, S. Kaufman, S.C. Juan, Y. Sun, J. Tarpley, L. Martin, K. Christensen, J. McCabe, P.J. Kostenuik, H. Hsu, F. Fletcher, C.R. Dunstan, D.L. Lacey, and W.J. Boyle RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism Proc. Natl. Acad. Sci. U. S. A. 97 2000 1566 1571
20. P. Damonte, J.P. Gregg, A.D. Borowsky, B.A. Keister, and R.D. Cardiff EMT tumorigenesis in the mouse mammary gland Lab. Invest. 87 2007 1218 1226
21. D.L. Lacey, E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, R. Elliot, A. Colombero, G. Elliot, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, C. Capparelli, A. Eli, Y.X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, J. Guo, J. Delaney, and W.J. Boyle Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 1998 165 176
22. D.M. Anderson, E. Maraskovsky, W.L. Billingsley, W.C. Dougall, M.E. Tometsko, E.R. Roux, M.C. Teepe, R.F. DuBose, D. Cosman, and L. Galibert A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature 390 1997 175 179
23. N. Nakagawa, M. Kinosaki, K. Yamaguchi, N. Shima, H. Yasuda, K. Yano, T. Morinaga, and K. Higashio RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis Biochem. Biophys. Res. Commun. 253 1998 395 400
24. D.L. Lacey, H.L. Tan, J. Lu, S. Kaufman, G. Van, W. Qiu, A. Rattan, S. Scully, F. Fletcher, T. Juan, M. Kelley, T.L. Burgess, W.J. Boyle, and A.J. Polverino Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo Am. J. Pathol. 157 2000 435 448
25. W. Liu, C. Xu, H. Zhao, P. Xia, R. Song, J. Gu, X. Liu, J. Bian, Y. Yuan, and Z. Liu Osteoprotegerin induces apoptosis of osteoclasts and osteoclast precursor cells via the fas/fas ligand pathway PLoS One 10 November (11) 2015 e0142519
26. E. Tsuda, M. Goto, S.I. Mochizuki, K. Yano, F. Kobayashi, T. Morinaga, and K. Higashio Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis Biochem. Biophys. Res. Commun. 234 1997 137 142
27. A. Lochter Plasticity of mammary epithelia during normal development and neoplastic progression Biochem. Cell Biol. 76 6 1998 997 1008
28. M.P. Ablett, J.K. Singh, and R.B. Clarke Stem cells in breast tumours: Are they ready for the clinic? Eur. J. Cancer 48 September (14) 2012 2104 2116
29. G. Sflomos, and C. Brisken A new achilles heel in breast cancer? Oncotarget 4 2013 1126 1127
30. G.W. Robinson, A.B. Karpf, and K. Kratochwil Regulation of mammary development by tissue interaction J. Mamm. Gland Biol. Neoplas. 4 1999 9 19
31. M.M. Morrison, C.D. Young, S. Wang, T. Sobolik, V.M. Sanchez, D.J. Hicks, R.S. Cook, and D.M. Brantley-Sieders mTOR directs breast morphogenesis through the PKC-alpha-Rac1 signaling axis PLoS Genet. 11 July (7) 2015 e1005291
32. M.C. Neville Physiology of lactation Clin. Perinatol. 26 1999 251 279
33. J.E. Fata, Y.Y. Kong, J. Li, T. Sasaki, J. Irie-Sasaki, R.A. Moorehead, R. Elliott, S. Scully, E.B. Voura, D.L. Lacey, W.J. Boyle, R. Khokha, and J.M. Penninger The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development Cell 103 2000 41 50
34. E. Gonzalez-Suarez, D. Branstetter, A. Armstrong, H. Dinh, H. Blumberg, and W.C. Dougall RANK overexpression in transgenic mice with mouse mammary tumor virus promoter controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini Mol. Cell. Biol. 27 4 2007 1442 1454
35. J.E. Fata, Y.Y. Kong, J. Li, T. Sasaki, J. Irie-Sasaki, R.A. Moorehead, R. Elliott, S. Scully, E.B. Voura, D.L. Lacey, W.J. Boyle, R. Khokha, and J.M. Penninger The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development Cell 103 2000 41 50
36. G. Karsenty The genetic transformation of bone biology Genes Dev. 13 1999 3037 3051
37. G.D. Roodman Cell biology of the osteoclast Exp. Hematol. 27 1999 1229 1241
38. F.P. Ross RANKing the importance of measles virus in Paget's disease J. Clin. Invest. 105 2000 555 558
39. W.C. Dougall Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis Clin. Cancer Res. 18 2012 326 335
40. M. Beleut, R.D. Rajaram, M. Caikovski, A. Ayyanan, D. Germano, Y. Choi, and et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland Proc. Natl. Acad. Sci. U. S. A. 107 2010 2989 2994
41. E. Gonzalez-Suarez, A.P. Jacob, J. Jones, R. Miller, M.P. Roudier-Meyer, R. Erwert, J. Pinkas, D. Branstetter, and W.C. Dougall RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis Nature 468 2010 103 107
42. A. Mukherjee, S.M. Soyal, J. Li, Y. Ying, B. He, F.J. DeMayo, and et al. Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression FASEB J. 24 2010 4408 4419
43. H. Hu, J. Wang, A. Gupta, A. Shidfar, D. Branstetter, and et al. RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase Breast Cancer Res. Treat. 146 2014 515 523
44. Y. Cao, G. Bonizzi, T.N. Seagroves, F.R. Greten, R. Johnson, E.V. Schmidt, and M. Karin IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development Cell 107 2001 763 775
45. Y. Cao, and et al. IκB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumorinitiating cells Proc. Natl. Acad. Sci. U. S. A. 104 2007 15852 15857
46. N.S. Kim, and et al. Receptor activator of NF-κB ligand regulates the proliferation of mammary epithelial cells via Id2 Mol. Cell. Biol. 26 2006 1002 1013
47. Y. Yokota, and et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2 Nature 397 1999 702 706
48. M.L. Asselin-Labat, F. Vaillant, J.M. Sheridan, B. Pal, D. Wu, E.R. Simpson, and et al. Control of mammary stem cell function by steroid hormone signalling Nature 465 2010 798 802
49. P.A. Joshi, H.W. Jackson, A.G. Beristain, M.A. Di Grappa, P.A. Mote, C.L. Clarke, and et al. Progesterone induces adult mammary stem cell expansion Nature 465 2010 803 807
50. Y. Hikosaka, and et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator Immunity 29 2008 438 450
51. R. Fernandez-Valdivia, A. Mukherjee, Y. Ying, J. Li, M. Paquet, F.J. DeMayo, and J.P. Lydon The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse Dev. Biol. 328 2009 127 139
52. A. Jemal, and et al. Cancer statistics CA Cancer J. Clin. 59 2009 225 249
53. U. Veronesi, P. Boyle, A. Goldhirsch, R. Orecchia, and G. Viale Breast cancer Lancet 365 2005 1727 1741
54. J.L. Kelsey, M.D. Gammon, and E.M. John Reproductive factors and breast cancer Epidemiol. Rev. 15 1993 36 47
55. J.C. Stevenson, H.N. Hodis, J.H. Pickar, and R.A. Lobo HRT and breast cancer risk: A realistic perspective Climacteric 14 December (6) 2011 633 636
56. D. Schramek, A. Leibbrandt, V. Sigl, L. Kenner, J.A. Pospisilik, H.J. Lee, R. Hanada, P.A. Joshi, A. Aliprantis, L. Glimcher, M. Pasparakis, R. Khokha, C.J. Ormandy, M. Widschwendter, G. Schett, and J.M. Penninger Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer Nature 468 2010 98 102
57. B. Dave, V. Mittal, N.M. Tan, and J.C. Chang Epithelial-mesenchymal transition, cancer stem cells and treatment resistance Breast Cancer Res. 14 2012 202
58. Y.Y. Kong, and et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 1999 315 323
59. C. Brisken, and S. Duss Stem cells and the stemcell niche in the breast: An integrated hormonal and developmental perspective Stem Cell Rev. 3 2007 147 156
60. M. Palafox, I. Ferrer, P. Pellegrini, S. Vila, S. Hernandez-Ortega, A. Urruticoechea, F. Climent, M.T. Soler, P. Muñoz, F. Viñals, M. Tometsko, D. Branstetter, W.C. Dougall, and E. González-Suárez RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis Cancer Res. 72 2012 2879 2888
61. J.C. Chang, E.C. Wooten, A. Tsimelzon, S.G. Hilsenbeck, M.C. Gutierrez, Y.L. Tham, M. Kalidas, R. Elledge, S. Mohsin, C.K. Osborne, G.C. Chamness, D.C. Allred, M.T. Lewis, H. Wong, and P. O'Connell Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients J. Clin. Oncol. 23 2005 1169 1177
62. X. Li, M.T. Lewis, J. Huang, C. Gutierrez, C.K. Osborne, M.F. Wu, S.G. Hilsenbeck, A. Pavlick, X. Zhang, G.C. Chamness, H. Wong, J. Rosen, and J.C. Chang Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J. Natl. Cancer Inst. 100 2008 672 679
63. Toshiyuki Yoneda, Soichi Tanaka, and Kenji Hata Role of RANKL/RANK in primary and secondary breast cancer World J. Orthop. 4 4 2013 178 185
64. X. Ye, and R.A. Weinberg Epithelial-mesenchymal plasticity: A central regulator of cancer progression Trends Cell Biol. 25 November (11) 2015 675 686
65. J.M. Lee, S. Dedhar, R. Kalluri, and E.W. Thompson The epithelial-mesenchymal transition: new insights in signaling, development, and disease J. Cell Biol. 172 2006 973 981
66. M. Guarino, B. Rubino, and G. Ballabio The role of epithelial-mesenchymal transition in cancer pathology Pathology 39 2007 305 318
67. M.I. Kokkinos, R. Wafai, M.K. Wong, D.F. Newgreen, E.W. Thompson, and M. Waltham Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo Cells Tissues Organs 185 2007 191 203
68. D. Sarrio, S.M. Rodriguez-Pinilla, D. Hardisson, A. Cano, G. Moreno-Bueno, and J. Palacios Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype Cancer Res. 68 2008 989 997
69. A.J. Trimboli, K. Fukino, A. de Bruin, G. Wei, L. Shen, S.M. Tanner, N. Creasap, T.J. Rosol, M.L. Robinson, C. Eng, M.C. Ostrowski, and G. Leone Direct evidence for epithelial-mesenchymal transitions in breast cancer Cancer Res. 68 2008 937 945
70. R. Kalluri, and E.G. Neilson Epithelial-mesenchymal transition and its implications for fibrosis J. Clin. Invest. 112 2003 1776 1784
71. E.D. Hay An overview of epithelio-mesenchymal transformation Acta Anat. (Basel.) 154 1995 8 20
72. C.J. Creighton, X. Li, M. Landis, J.M. Dixon, V.M. Neumeister, A. Sjolund, D.L. Rimm, H. Wong, A. Rodriguez, J.I. Herschkowitz, C. Fan, X. Zhang, X. He, A. Pavlick, M.C. Gutierrez, L. Renshaw, A.A. Larionov, D. Faratian, S.G. Hilsenbeck, C.M. Perou, M.T. Lewis, J.M. Rosen, and J.C. Chang Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features Proc. Natl. Acad. Sci. U. S. A. 106 2009 13820 13825
73. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
74. D. Holstead-Jones, and et al. Regulation of cancer cell migration and bone metastasis by RANKL Nature 440 2006 692 696
75. S.S. Cross, and et al. Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables J. Clin. Pathol. 59 2006 716 720
76. C. Van Poznak, and et al. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours J. Clin. Pathol. 59 2006 56 63
77. W. Tan, and et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling Nature 470 2011 548 553
78. T. Tanos, G. Sflomos, P.C. Echeverria, A. Ayyanan, M. Gutierrez, J.F. Delaloye, and et al. Progesterone/RANKL is a major regulatory axis in the human breast Sci. Transl. Med. 182 2013 182ra55
79. M. Windschwendter, M. Burnell, L. Fraser, and et al. Osteoprotegrin (OPG), the endogenous inhibitor of receptor activator of NF-kB ligand (RANKL) is dyregulated in BRCA mutation carriers EBioMedicine 2 2015 1331 1339
80. P.J. Kostenuik, H.Q. Nguyen, J. McCabe, K.S. Warmington, C. Kurahara, N. Sun, and et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL J. Bone Min. Res. 24 2009 182 195
81. J. Lam, C.A. Nelson, F.P. Ross, S.L. Teitelbaum, and D.H. Fremont Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity J. Clin. Invest. 108 2001 971 979
82. D.L. Lacey, W.J. Boyle, W.S. Simonet, P.J. Kostenuik, W.C. Dougall, J.K. Sullivan, J. San Martin, and R. Dansey Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab Nat. Rev. Drug Discov. 11 2012 401 419
83. D.R. Mould, and B. Green Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development BioDrugs 24 2010 23 39
84. R. Baron, S. Ferrari, and R.G. Russell Denosumab and bisphosphonates: different mechanisms of action and effects Bone 48 2011 677 692
85. F. Saad, J.E. Brown, C. Van Poznak, T. Ibrahim, S.M. Stemmer, A.T. Stopeck, I.J. Diel, S. Takahashi, N. Shore, D.H. Henry, C.H. Barrios, T. Facon, F. Senecal, K. Fizazi, L. Zhou, A. Daniels, P. Carrière, and R. Dansey Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases Ann. Oncol. 23 2012 1341 1347
86. A. Lipton, K. Fizazi, A.T. Stopeck, D.H. Henry, J.E. Brown, D.A. Yardley, G.E. Richardson, S. Siena, P. Maroto, M. Clemens, B. Bilynskyy, V. Charu, P. Beuzeboc, M. Rader, M. Viniegra, F. Saad, C. Ke, A. Braun, and S. Jun Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials Eur. J. Cancer 48 2012 3082 3092
87. D. Diédhiou, T. Cuny, A. Sarr, S. Norou Diop, M. Klein, and G. Weryha Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review Ann. Endocrinol. (Paris) 76 December (6) 2015 650 657
88. G. Eghbali-Fatourechi, and et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women J. Clin. Invest. 111 2003 1221 1230
89. B.M. Abdallah, and et al. Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures Calcif. Tissue Int. 76 2005 90 97
90. X. Li, and et al. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin Bone 45 2009 669 676
91. M.S. Ominsky, and et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats J. Bone Min. Res. 23 2008 672 682
92. V. Proell, and et al. Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats Bone 45 2009 677 681
93. P.J. Kostenuik, and et al. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody Bone 49 2011 151 161
94. M.S. Ominsky, and et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys Bone 49 2011 162 173
95. W.S. Simonet, and et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
96. P.V. Hauschka, A.E. Mavrakos, M.D. Iafrati, S.E. Doleman, and M. Klagsbrun Growth factors in bone matrix: isolation of multiple types by affinity chromatography on heparin-sepharose J. Biol. Chem. 261 1986 12665 12674
97. T. Yoneda, and T. Hiraga Crosstalk between cancer cells and bone microenvironment in bone metastasis Biochem. Biophys. Res. Commun. 328 2005 679 687
98. G.R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities Nat. Rev. Cancer 2 2002 584 593
99. G.D. Roodman Mechanisms of bone metastasis N. Engl. J. Med. 350 2004 1655 1664
100. K.N. Weilbaecher, T.A. Guise, and L.K. McCauley Cancer to bone: A fatal attraction Nat. Rev. Cancer 11 2011 411 425
101. C.R. Good, R.J. O'Keefe, J.E. Puzas, E.M. Schwarz, and R.N. Rosier Immunohistochemical study of receptor activator of nuclear factor κ B ligand (RANK L) in human osteolytic bone tumors J. Surg. Oncol. 79 2002 174 179
102. E. Grimaud, and et al. Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis Am. J. Pathol. 163 2003 2021 2031
103. L. Huang, Y.Y. Cheng, L.T. Chow, M.H. Zheng, and S.M. Kumta Tumour cells produce receptor activator of NF κB ligand (RANKL) in skeletal metastases J. Clin. Pathol. 55 2002 877 878
104. S. Kitazawa, and R. Kitazawa RANK ligand is a prerequisite for cancer-associated osteolytic lesions J. Pathol. 198 2002 228 236
105. T. Ohshiba, C. Miyaura, M. Inada, and A. Ito Role of RANKL-induced osteoclast formation and MMPdependent matrix degradation in bone destruction by breast cancer metastasis Br. J. Cancer 88 2003 1318 1326
106. R.N. Pearse, and et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression Proc. Natl Acad. Sci. U. S. A. 98 2001 11581 11586
107. J. Zhu, and et al. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases J. Biol. Chem. 282 2007 26656 26664
108. A.E. Kearns, S. Khosla, and P.J. Kostenuik Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease Endocr. Rev. 29 2008 155 192
109. J. Canon, and et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis Clin. Exp. Metastasis 25 2008 119 129
110. Y. Zheng, and et al. Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone Cancer Res. 67 2007 9542 9548